{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-150433","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.117054+00:00","generated_at":"2026-06-01T07:21:22.271005+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA approves higher max daily dose of FIRDAPSE for LEMS to 100 mg","bullets":["FDA approved sNDA increasing FIRDAPSE max daily dose from 80 mg to 100 mg for adults and peds >45 kg with LEMS.","FIRDAPSE is the only U.S.-approved treatment for LEMS; expanded dosing offers greater treatment flexibility.","CEO Richard Daly states approval will have meaningful impact on LEMS patient outcomes.","Catalyst Pathways patient support program available for eligible patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-150433","json":"https://secwatch.observer/filing/0001193125-24-150433.json","markdown":"https://secwatch.observer/filing/0001193125-24-150433.md","text":"https://secwatch.observer/filing/0001193125-24-150433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524150433/0001193125-24-150433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524150433/d831301d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:21:22.271005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}